Synklino
Lyngby
About Synklino
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $33.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2022)
- Website: synklino.com
- Phone: +45 20 12 16 56
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/synklino-2998 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.